関連する実験動画
Updated: Sep 10, 2025

05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
7.6K
GLP-1媒介のインスリン分泌を増強する
Abigail Pearce1, Poonam Kumari2, Claudia M Sisk1
1Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK.
The Journal of biological chemistry
|August 20, 2025
まとめ
レセプター活性調節タンパク質3 (RAMP3) は,グルカゴン様ペプチド-1受容体 (GLP-1R) のシグナル伝達を調節し,インスリン分泌を増強する. この相互作用は,糖尿病と肥満の現在のGLP- 1R療法に関連した副作用を軽減する可能性があります.
科学分野:
- 薬理学について
- 内分泌学
- 分子生物学
背景:
- グルカゴン型ペプチド-1受容体 (GLP- 1R) アゴニストは糖尿病と肥満に有効ですが,副作用を引き起こす.
- 受容体活性調節タンパク質 (RAMPs) は,アゴニストの結合とシグナル伝達を変化させ,潜在的に望ましくない効果を軽減します.
- RAMPは,より選択的なGLP-1R治療法を開発するための戦略を提供します.
研究 の 目的:
- GLP-1RとRAMP3の相互作用を調査する.
- RAMP3が GLP-1Rの信号伝達経路にどのように影響するかを決定する.
- 代謝疾患におけるGLP-1R-RAMP3相互作用の治療の可能性を評価する.
主な方法:
- GLP- 1RとRAMP3の相互作用を確認するための共免疫プレシピテーション.
- 細胞内カルシウム (Ca2+) と周期性アデノシンモノフォスファート (cAMP) 信号の測定
- GLP-1R活性化時のGタンパク質結合 (Gαs,Gαq,Gαi) の分析
- グルコースとインスリン耐性試験のためのRAMP3ノックアウトマウスを用いたin vivo試験.
主要な成果:
- GLP-1Rは,細胞表面でRAMP3と機能的なヘテロダイマーを形成する.
- RAMP3の発現は,GLP-1RのシグナリングをcAMPからCa2+の動員にシフトさせる.
- RAMP3は,GLP-1誘発のインスリン分泌をGタンパク質結合を変化させることで強化する.
- ランプ3ノックアウトマウスは,グルコースとインスリン耐性テストでGLP-1に対する感受性が低下した.
結論:
- RAMP3はGLP- 1R機能の重要な調節剤として作用する.
- GLP- 1R- RAMP3の相互作用は,代謝制御を改善するための新しい治療目標を示しています.
- この相互作用を理解することで,安全性プロファイルが向上した次世代のGLP-1Rベースの薬の設計を導くことができます.
関連する概念動画
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K

